Please assess the completion status of the following clinical trial:

Trial Title: Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with idiopathic PD without any known cause for Parkinsonism.~2. At least 30 years old at the time of PD diagnosis.~3. Currently being treated with:~   * an LD dosing frequency of at least four times a day~  * at least one dose of CD-LD ER daily~  * requiring a total daily LD dose of at least 400 mg~  * stable regimen for at least 4 weeks prior to Screening~4. Concomitant therapy with amantadine, anticholinergics, selective monoamine oxidase (MAO) type B inhibitors (e.g., selegiline, rasagiline) or dopamine agonists is allowed as long as the doses and regimens have been stable for at least 4 weeks prior to Screening and the therapy is intended to be constant throughout the course of the study.~5. Agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.~Exclusion Criteria:~1. Pregnant or breastfeeding~2. Diagnosed with atypical Parkinsonism or any known secondary Parkinsonian syndrome.~3. Nonresponsive to LD therapy.~4. Prior functional neurosurgical treatment for PD (e.g., ablation or deep brain stimulation) or if such procedures are anticipated during study participation.~5. Planning to take during participation in the clinical study: any controlled-release LD product, additional CD or benserazide, entacapone or tolcapone, nonselective MAO inhibitors, or antipsychotics including neuroleptic agents for the purpose of treating psychosis or bipolar disorder.~6. Any evidence of suicidal behavior within 6 months of entering the study.~7. Allergic or hypersensitive to to CD, LD, entacapone, riboflavin, Yellow Dye #5 (tartrazine), citrus fruit or grape juice.~8. History of or currently active psychosis.~9. Active or history of peptic ulcers or surgical procedure of the stomach, the small intestine or the large intestine.~10. Active or history of narrow-angle glaucoma.~11. History of malignant melanoma or a suspicious undiagnosed skin lesion.~12. History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome and/or nontraumatic rhabdomyolysis.~13. Abnormal kidney function~14. Severe hepatic impairment.~15. Received any investigational medications during the 4 weeks prior to Screening.~16. Previously enrolled in IPX066 studies.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPX066 (Type: EXPERIMENTAL): Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.

Based on this trial design, predict the completion outcome and termination type (if applicable).